Valeant acquired the company, Sprout Pharmaceuticals, two years ago for $1 billion. At the time, Valeant executives had high hopes for Sprout’s female libido drug, Addyi. However, the drug has seen weak sales, spurring former Sprout investors to sue Valeant over the marketing for Addyi.
Through the new deal, Valeant will return Sprout — and the rights to Addyi —to its former shareholders and give the company a $25 million loan to fund initial operating expenses. Valeant will receive a 6 percent royalty on global sales of the drug beginning 18 months after finalizing the deal with Sprout.
“Returning Sprout to its former owners will enable us to further streamline our portfolio and reduce complexity in our business,” said Valeant CEO Joe Papa, adding that the company aims to focus on core business areas such as eye health, gastroenterology and dermatology.
More articles on supply chain:
FDA approves Valeant’s glaucoma drug: 4 things to know
CVS stores to offer next-day drug delivery in 2018: 4 things to know
6 drug, devicemakers in the headlines
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.